<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><description>It takes nothing to join the crowd, but it takes everything to stand alone</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 09 Apr 2021 07:23:35 +0800</pubDate><image><url>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</url><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>2021年中国mRNA治疗行业研究报告</title><link>https://mp.weixin.qq.com/s/F8Hms_HlCwNbklqdou6-6g</link><description></description><content:encoded><![CDATA[2021年中国mRNA治疗行业研究报告]]></content:encoded><pubDate>Thu, 08 Apr 2021 22:21:00 +0800</pubDate></item><item><title>药物研发中如何确定创新药及仿制药杂质限度</title><link>https://mp.weixin.qq.com/s/bjRbXSDcKva91Z2eXeH6XA</link><description></description><content:encoded><![CDATA[药物研发中如何确定创新药及仿制药杂质限度]]></content:encoded><pubDate>Thu, 08 Apr 2021 22:21:00 +0800</pubDate></item><item><title>特异靶向KRAS-G12C突变的抗肿瘤药物研究进展</title><link>https://mp.weixin.qq.com/s/oEl-YptuZfmQ--Ey-K_r_Q</link><description></description><content:encoded><![CDATA[特异靶向KRAS-G12C突变的抗肿瘤药物研究进展]]></content:encoded><pubDate>Thu, 08 Apr 2021 22:21:00 +0800</pubDate></item><item><title>基因治疗制品申报IND/NDA药学评价要点</title><link>https://mp.weixin.qq.com/s/yJZ5YBPw189A75p5-X-4Nw</link><description></description><content:encoded><![CDATA[基因治疗制品申报IND/NDA药学评价要点]]></content:encoded><pubDate>Wed, 07 Apr 2021 20:31:22 +0800</pubDate></item><item><title>药物是怎样从研发到上市的？</title><link>https://mp.weixin.qq.com/s/dP-_iM106ZISuXq0k8_FpQ</link><description></description><content:encoded><![CDATA[药物是怎样从研发到上市的？]]></content:encoded><pubDate>Wed, 07 Apr 2021 20:31:22 +0800</pubDate></item><item><title>研发过程数据可靠性的管理与思考</title><link>https://mp.weixin.qq.com/s/9cr32G68XBg4bp9Gs5BS8w</link><description></description><content:encoded><![CDATA[研发过程数据可靠性的管理与思考]]></content:encoded><pubDate>Wed, 07 Apr 2021 20:31:22 +0800</pubDate></item><item><title>阿达木单抗注射液申请上市技术审评报告</title><link>https://mp.weixin.qq.com/s/SJIR3LjdD9zgS5B8ck5CPw</link><description></description><content:encoded><![CDATA[阿达木单抗注射液申请上市技术审评报告]]></content:encoded><pubDate>Tue, 06 Apr 2021 22:16:44 +0800</pubDate></item><item><title>Nature：抗体偶联药开发概览及市场预测</title><link>https://mp.weixin.qq.com/s/WQLVX5486xqHMqzoM5tYgw</link><description></description><content:encoded><![CDATA[Nature：抗体偶联药开发概览及市场预测]]></content:encoded><pubDate>Tue, 06 Apr 2021 22:16:44 +0800</pubDate></item><item><title>新药研发流程及研发项目管理时间轴</title><link>https://mp.weixin.qq.com/s/v08Mgllfh00vKBhvkuoywg</link><description></description><content:encoded><![CDATA[新药研发流程及研发项目管理时间轴]]></content:encoded><pubDate>Tue, 06 Apr 2021 22:16:44 +0800</pubDate></item><item><title>小分子药物的困境与出路</title><link>https://mp.weixin.qq.com/s/chgUWeUnNrNrwr1eaZCwPw</link><description></description><content:encoded><![CDATA[小分子药物的困境与出路]]></content:encoded><pubDate>Mon, 05 Apr 2021 17:27:42 +0800</pubDate></item><item><title>CDE：ADC药物PK研究要点</title><link>https://mp.weixin.qq.com/s/oORWE9owDyNXJk9srSdQrA</link><description></description><content:encoded><![CDATA[CDE：ADC药物PK研究要点]]></content:encoded><pubDate>Mon, 05 Apr 2021 17:27:42 +0800</pubDate></item><item><title>化学原料药杂质研究与控制策略</title><link>https://mp.weixin.qq.com/s/_13n3hi470v568AD0UaZjQ</link><description></description><content:encoded><![CDATA[化学原料药杂质研究与控制策略]]></content:encoded><pubDate>Mon, 05 Apr 2021 17:27:42 +0800</pubDate></item><item><title>梳理 | 2类创新药行业报告汇总</title><link>https://mp.weixin.qq.com/s/zm2Bsa9TrDppMa7bkq79Mg</link><description></description><content:encoded><![CDATA[梳理 | 2类创新药行业报告汇总]]></content:encoded><pubDate>Thu, 01 Apr 2021 20:34:06 +0800</pubDate></item><item><title>药物制剂中药物与辅料相互作用的研究进展</title><link>https://mp.weixin.qq.com/s/2TvdzetzsI8BqO9HejJbFA</link><description></description><content:encoded><![CDATA[药物制剂中药物与辅料相互作用的研究进展]]></content:encoded><pubDate>Thu, 01 Apr 2021 20:34:06 +0800</pubDate></item><item><title>国内外吸入剂BE研究要点分析</title><link>https://mp.weixin.qq.com/s/GG8osueSKdlEJzbrXAKGMA</link><description></description><content:encoded><![CDATA[国内外吸入剂BE研究要点分析]]></content:encoded><pubDate>Thu, 01 Apr 2021 20:34:06 +0800</pubDate></item><item><title>CDE解答124个技术问题</title><link>https://mp.weixin.qq.com/s/g0B_j4Ph9C5ug42YBjU79A</link><description></description><content:encoded><![CDATA[CDE解答124个技术问题]]></content:encoded><pubDate>Thu, 01 Apr 2021 20:34:06 +0800</pubDate></item><item><title>刚刚！CDE发布纳米药物3大指导原则！纳米药物质量控制、非临床安评、非临床药代动力学！</title><link>https://mp.weixin.qq.com/s/kJZT4zVuIFW3Qymsd9sEJw</link><description></description><content:encoded><![CDATA[刚刚！CDE发布纳米药物3大指导原则！纳米药物质量控制、非临床安评、非临床药代动力学！]]></content:encoded><pubDate>Wed, 31 Mar 2021 20:58:03 +0800</pubDate></item><item><title>杂质研究与控制 —基本思路与策略</title><link>https://mp.weixin.qq.com/s/MtBcGFKuqlck0aYYOb0EQw</link><description></description><content:encoded><![CDATA[杂质研究与控制 —基本思路与策略]]></content:encoded><pubDate>Wed, 31 Mar 2021 20:58:03 +0800</pubDate></item><item><title>质量人必备的14张图，赶紧收藏！</title><link>https://mp.weixin.qq.com/s/X59_TR4SN78qo98tWfjbyQ</link><description></description><content:encoded><![CDATA[质量人必备的14张图，赶紧收藏！]]></content:encoded><pubDate>Wed, 31 Mar 2021 20:58:03 +0800</pubDate></item><item><title>化学药物生产现场检查问答总结</title><link>https://mp.weixin.qq.com/s/CihbWH7WPPi38LuRE0nv_w</link><description></description><content:encoded><![CDATA[化学药物生产现场检查问答总结]]></content:encoded><pubDate>Tue, 30 Mar 2021 20:48:17 +0800</pubDate></item></channel></rss>